Evidence map›Paper›PMID 31530861›Full record

Trial reportLeukemia2020

A novel lymphoma-associated macrophage interaction signature (LAMIS) provides robust risk prognostication in diffuse large B-cell lymphoma clinical trial cohorts of the DSHNHL.

Annette M Staiger, Michael Altenbuchinger, Marita Ziepert, Christian Kohler, Heike Horn, Michael Huttner, Katrin S Hüttl, Gunther Glehr, Wolfram Klapper, Monika Szczepanowski and 16 more

Abstract readClinical Trial
PubMed Publisher
In one paragraph

Trial report in Leukemia, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. An overview and a roadmap for artificial intelligence in hematology and oncology.Journal of cancer research and clinical oncology · 2023
    Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Annette M Staiger *Department of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.ORCID http://orcid.org/0000-0002-5896-3200
Michael Altenbuchinger *Statistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Marita Ziepert *Institute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Christian KohlerStatistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Heike HornDr Margarete Fischer-Bosch Institute of Clinical Pharmacology, University of Tuebingen, Stuttgart, Germany.
Michael HuttnerStatistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Katrin S HüttlDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany.
Gunther GlehrStatistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Wolfram KlapperInstitute of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0001-7208-4117
Monika SzczepanowskiInstitute of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Julia RichterInstitute of Pathology, Hematopathology Section and Lymph Node Registry, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID http://orcid.org/0000-0002-9543-4084
Harald SteinPathodiagnostik Berlin, Berlin, Germany.
Alfred C FellerHaematopathologie Luebeck, Luebeck, Germany.
Peter MöllerInstitute of Pathology, Universitätsklinikum Ulm, Ulm, Germany.
Martin-Leo HansmannDr. Senckenberg Institute of Pathology, Goethe University Hospital, Frankfurt, Germany.
Viola PoeschelDSHNHL Studiensekretariat, Universitätsklinikum des Saarlandes, Homburg, Germany.
Gerhard HeldDSHNHL Studiensekretariat, Universitätsklinikum des Saarlandes, Homburg, Germany.
Markus LoefflerInstitute for Medical Informatics, Statistics and Epidemiology, University of Leipzig, Leipzig, Germany.
Norbert SchmitzDepartment of Medicine A, University Hospital Muenster, Muenster, Germany.
Lorenz TrümperDepartment of Hematology and Oncology, Georg-August Universität, Göttingen, Germany.
Tobias PukropDepartment of Internal Medicine III, Universitätsklinikum Regensburg, Regensburg, Germany.
Andreas RosenwaldInstitute of Pathology, Universität Würzburg and Comprehensive Cancer Center Mainfranken (CCCMF), Würzburg, Germany.
German OttDepartment of Clinical Pathology, Robert-Bosch-Krankenhaus, Stuttgart, Germany. German.Ott@rbk.de.
Rainer SpangStatistical Bioinformatics, Institute of Functional Genomics, University of Regensburg, Regensburg, Germany.
Emed Demonstrator Project
German High Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL)

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a disease with heterogeneous outcome. Stromal signatures have been correlated to survival in DLBCL. Their use, however, is hampered by the lack of assays for formalin-fixed paraffin-embedded material (FFPE). We constructed a lymphoma-associated macrophage interaction signature (LAMIS) interrogating features of the microenvironment using a NanoString assay applicable to FFPE. The clinical impact of the signature could be validated in a cohort of 466 patients enrolled in prospective clinical trials of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Patients with high expression of the signature (LAMIS

Indexed as

FemaleHumansLymphoma, Large B-Cell, DiffuseLymphoma, Non-HodgkinMacrophagesMaleMiddle AgedPrognosisProspective StudiesProto-Oncogene Proteins c-mycTumor MicroenvironmentProto-Oncogene Proteins c-myc

Identifiers

PMID31530861

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.